文献速递乳腺癌

依维莫司联合辅助内分泌治疗用于高危激素受体阳性人表皮生长因子受体2阴性原发性乳腺癌患者

Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer.
PubMed 文献 · J Clin Oncol · 2022-05-23

这项随机双盲III期研究纳入1278例高危激素受体阳性/HER2阴性原发性乳腺癌患者,比较依维莫司或安慰剂联合标准内分泌治疗2年的疗效。3年无病生存率依维莫司组88% vs 安慰剂组89%(HR 0.95,95%CI 0.69-1.32,P=.77),无显著差异;依维莫司组3级及以上不良事件29.9% vs 15.9%(P<.001),53.4%患者提前永久停用依维莫司。结论为辅助内分泌治疗加用依维莫司未改善无病生存,不能推荐用于辅助治疗。

要点

  • 3年无病生存率依维莫司组88% vs 安慰剂组89%,无显著差异(HR 0.95,95%CI 0.69-1.32,P=.77)。
  • 依维莫司组3级及以上不良事件29.9% vs 安慰剂组15.9%(P<.001)。
  • 53.4%依维莫司组患者提前永久停用试验治疗,安慰剂组为22.3%。

核心结论

  • 在高危激素受体阳性/HER2阴性原发性乳腺癌患者中,辅助内分泌治疗加用依维莫司未改善无病生存。
  • 依维莫司组耐受性令人担忧,超过半数患者在研究完成前停用依维莫司。
  • 依维莫司不能推荐用于辅助治疗。

研究设计与样本

  • 随机双盲III期研究,纳入高危、激素受体阳性、人表皮生长因子受体2阴性原发性乳腺癌女性患者。
  • 患者随机分配接受依维莫司或安慰剂治疗2年,联合标准内分泌治疗。
  • 分层因素包括内分泌治疗药物、新辅助 vs 辅助化疗、孕激素受体状态、随机分组前内分泌治疗时长及淋巴结受累情况。
  • 主要终点为无病生存期(DFS);试验注册号ClinicalTrials.gov NCT01805271。
  • 2013年6月至2020年3月间共1278例患者随机分配。

主要发现

  • 第一次 interim 分析时因无效而终止试验,数据快照完成后进行完整分析。
  • 147例患者报告DFS事件;3年DFS依维莫司组88%(95%CI 85-91)vs 安慰剂组89%(95%CI 86-91),无显著差异(HR 0.95,95%CI 0.69-1.32,P=.77)。
  • 3级及以上不良事件依维莫司组29.9% vs 安慰剂组15.9%(P<.001)。
  • 依维莫司组53.4%患者提前永久停用试验治疗,安慰剂组为22.3%。

关键数值与推荐

  • 3年DFS:依维莫司组88%(95%CI 85-91)vs 安慰剂组89%(95%CI 86-91)。
  • DFS风险比HR 0.95(95%CI 0.69-1.32,P=.77)。
  • 3级及以上不良事件发生率:依维莫司组29.9% vs 安慰剂组15.9%(P<.001)。
  • 提前永久停用试验治疗比例:依维莫司组53.4% vs 安慰剂组22.3%。

临床怎么用

  • 作者结论指出,依维莫司不能推荐用于辅助治疗。

局限性

  • 试验在第一次 interim 分析时因无效而终止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor-resistant metastatic breast cancer. However, the benefit of adding everolimus to ET in the adjuvant setting in early breast cancer is unknown. PATIENTS AND METHODS: In this randomized double-blind phase III study, women with high-risk, hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer were randomly assigned to everolimus or placebo for 2 years combined with standard ET. Stratification factors included ET agent, receipt of neoadjuvant versus adjuvant chemotherapy, progesterone receptor status, duration of ET before random assignment, and lymph node involvement. The primary end point was disease-free survival (DFS). The trial is registered with ClinicalTrials.gov (identifier: NCT01805271). RESULTS: Between June 2013 and March 2020, 1,278 patients were randomly allocated to receive everolimus or placebo. At the first interim analysis, the trial was stopped for futility and a full analysis undertaken once data snapshot complete. One hundred forty-seven patients have had a DFS event reported and at 3 years, DFS did not differ between patients who received ET plus everolimus (88% [95% CI, 85 to 91]) or ET plus placebo (89% [95% CI, 86 to 91; hazard ratio, 0.95; 95% CI, 0.69 to 1.32; P = .77]). Grade ≥ 3 adverse events were reported in 22.9% of patients (29.9% with everolimus v 15.9% with placebo, P < .001). 53.4% everolimus-treated patients permanently discontinued experimental treatment early compared with placebo-treated 22.3%. CONCLUSION: Among high-risk patients, everolimus added to adjuvant ET did not improve DFS. Tolerability was a concern, with more than half of patients stopping everolimus before study completion. Everolimus cannot be recommended in the adjuvant setting.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bachelot T, Cottu P, Chabaud S, et al. Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. J Clin Oncol. 2022. PMID: 35605174. doi:10.1200/JCO.21.02179

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。